METABOLISMO ÓSEO, VASCULAR, ENFERMEDADES INFLAMATORIAS CRÓNICAS Y BIOMARCADORES
METOSEO
Brigham and Women's Hospital
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Brigham and Women's Hospital (7)
2015
-
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
American Heart Journal, Vol. 169, Núm. 5, pp. 631-638.e7
2014
-
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment
The Lancet Diabetes and Endocrinology, Vol. 2, Núm. 8, pp. 634-647
2012
-
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease
American Heart Journal, Vol. 164, Núm. 6
-
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial
JAMA - Journal of the American Medical Association, Vol. 307, Núm. 7, pp. 674-684
2011
-
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease
Clinical Trials, Vol. 8, Núm. 2, pp. 165-174
-
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
American Journal of Nephrology, Vol. 33, Núm. 2, pp. 139-149
2010
-
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial
Circulation, Vol. 121, Núm. 10, pp. 1176-1187